The role of T-cells in rheumatoid arthritis and the use of immunomodulating drugs

Drugs of Today

Volumn 35, Issue 4-5, 1999, Pages 295-307

  Yocum, David E ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 4; PLACEBO; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS; VACCINE;

ANTIFUNGAL ACTIVITY; ANTIGEN RECOGNITION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; HELPER CELL; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PATHOGENESIS; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; TRANSPLANTATION;

EID: 0032778830     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.4-5.552205     Document Type: Conference Paper

References (92)

1. Goronzy, J.J., Wey, C.M. T-cells in rheumatoid arthritis. Rheum Dis Clin North Am 1995, 21: 655-73.
2. Sakata, A., Sakata, K., Ping, H., Ohmura, T., Tsukano, M. Kakimoto, K. Successful induction of severe destructive arthritis by the transfer of in vitro-activated synovial T-cells from patients with rheumatoid arthritis in severe combined immunodeficient mice. Clin Exp Immunol 1996, 104: 247-54.
3. Häuselmann, H.J. Mechanisms of cartilage destruction and novel non-surgical therapeutic strategies to retard cartilage injury in rheumatoid arthritis. Curr Opin Rheum 1997, 9: 241-50.
4. Campion, G.V., Lebsack, M.E., Lookabaugh, J., Gordon, G., Catalano, M., IL-1Ra Arthritis Study Group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39: 1092-101.
5. Yocum, D.E., Allen, J.B., Wahl, S.M., Calandra, G.B., Wilder, R.L. Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats. Arthritis Rheum 1986, 29: 262-73.
6. Sigal, N.H. , Dumont, F.J. Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol 1992, 10: 519-60.
7. Braun, W., Kallen, J., Mikol, V., Walkinshau, M.D., Wuthrich, K. Three-dimensional structure and actions of immunosuppressants and their immunophilins. FASEB 1995, 9: 63-72.
8. Krönke, M., Leonard, W.J., Depper, J.M. et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1984, 81: 5214-18.
9. Lin, C.S., Boltz, R.C., Siekierka, J.J., Sigal, N.H. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T-lymphocytes. Cell Immunol 1991, 133: 269-84.
10. Kay, J.E., Kromwell, L., Doe, S.E.A. , Denyer, M. Inhibition of T- and B-lymphocyte proliferation by rapamycin. Immunology 1991, 72: 544-9.
11. Herold, K.C., Lancki, D.W., Moldwin, R.I., Fitch, F.W. Immunosuppressive effects of cyclosporin A on cloned T-cells. J Immunol 1986, 136: 1315-21.
12. Granelli-Piperno, A. In situ hybridization for interleukin-2 and interleukin-2 receptor mRNA in T-cells activated in the presence or absence of cyclosporin A. J Exp Med 1988, 168: 1649-58.
13. Tocci, M.J., Matkovich, D.A., Collier, K.A. et al. The immunosuppressant FK-506 selectively inhibits expression of early T-cell activation genes. J Immunol 1989, 143: 718-26.
14. Bierer, B.E., Mattila, P.S., Standaert, R.F. et al. Two distinct signal transmission pathways in T-lymphocytes are inhibited by complexes formed between an immunophilin and either FK-506 or rapamycin. Proc Natl Acad Sci USA 1990, 87: 9231-5.
15. Martel, R.R., Klicius, J., Galet, S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977, 55: 48-51.
16. Wicker, L.S., Boltz, R.C., Matt, V., Nichols, E.A., Peterson, L.B., Sigal, N.H. Suppression of B-cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol 1990, 20: 2277-83.
17. Dumont, F.J., Melino, M.R., Staruch, M.J., Koprak, S.L., Fischer, P.A., Sigal, N.H. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T-cells. J Immunol 1990, 144: 1418-24.
18. Kahan, B.D., Gibbons, S., Tejpal, N. et al. Synergistic interactions of cyclosporin and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991, 51: 232-9.
19. Hermann, B., Muller, W. Die therapie der chronischen polyarthritis mit cyclosporin A, einens neuen immun-suppressivum. Akt Rheumatol 1979, 4: 173-86.
20. Muller, W., Hermann, B. Cyclosporin A for psoriasis. New Engl J Med 1979, 301: 555.
21. Amor, B., Dougados, M. Cyclosporin in rheumatoid arthritis: Open trials with different dosages. In: Cyclosporin in Autoimmune Diseases. R. Schindler (Ed.). Springer: Berlin 1985, 283-7.
22. Dougados, M., Amor, B. Cyclosporin A in rheumatoid arthritis: preliminary clinical results of an open trial. Arthritis Rheum 1987, 30: 83-7.
23. Weinblatt, M.E., Coblyn, J.S., Fraser, P.A. et al. Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum 1987, 30: 11-17.
24. Bowles, C.A. Long-term treatment of rheumatoid arthritis with cyclosporin (CsA). Arthritis Rheum 1989, 32: S61.
25. Tugwell, P., Bombardier, C., Gent, M. et al. Low dose cyclosporin in rheumatoid arthritis: A pilot study. J Rheumatol 1987, 14: 1108-14.
26. Dougados, M., Duchesne, L., Awada, H., Amor, B. Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis. Ann Rheum Dis 1989, 48: 550-6.
27. Palestine, A.G., Austin, H.A., Balow, J.E. et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. New Engl J Med 1986, 314: 1293-8.
28. Førre, Ø., Bjerkhoel, F., Salvesen, C.F. et al. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 1987, 30: 88-92.
29. Van Rijthoven, A.W.A.M., Dijkmans, B.A.C., Goei The, H.S. et al. Cyclosporin treatment for rheumatoid arthritis: A placebo-controlled, double-blind, multicentre study. Ann Rheum Dis 1986, 45: 726-31.
30. Dougados, M., Awada, H., Amor, B. Cyclosporin in rheumatoid arthritis: A double-blind, placebo-controlled study in 52 patients. Ann Rheum Dis 1988, 47: 127-33.
31. Yocum, D.E., Klippel, J.H., Wilder, R.L. et al. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis: A randomized study. Ann Intern Med 1988, 109: 863-9.
32. Tugwell, P., Bombardier, C., Gent, M. et al. Low dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990, 335: 1051-5.
33. Førre, Ø., Norwegian Arthritis Disease Study Group. Cyclosporin as a disease modifier in rheumatoid arthritis. 2nd Cong Immunointervention in Autoimmune Dis (Paris) 1991, Abst 197.
34. Schattenkirchner, M., Kruger, K. Cyclosporin vs azathioprine in the treatment of rheumatoid arthritis: A controlled, double-blind study. 2nd Cong Immunointervention in Autoimmune Dis (Paris) 1991, Abst 198.
35. Van Rijthoven, A.W.A.M., Dijkmans, B.A.C., Goei The, H.S. et al. Comparison of cyclosporin and D-penicillamine for rheumatoid arthritis: A randomized, double-blind muticenter study. J Rheumatol 1991, 18: 815-20.
36. Panayi, G.S., Tugwell, P. An international consensus report: The use of cyclosporin A in rheumatoid arthritis. Br J Rheum 1993, 32 (Suppl. 1): 1-3.
37. Madhok, R., Torley, H.I., Capell, H.A. A study of the long-term efficacy and toxicity of cyclosporine A in rheumatoid arthritis. J Rheumatol 1991, 18: 1485-9.
38. Førre, Ø., Norwegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994, 37: 1506-12.
39. Landewé, R.B.M., Goei The, H.S., Van Rijthoven, A.W.AM., Breedveld, F.C., Dijkmans, A.C. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994, 37: 637-43.
40. Landewé, R.B.M., Goei The, H.S., Van Rijthoven, A.W.A.M., Breedveld, F.C., Dijkmans, B.A.C. Cyclosporine in early rheumatoid arthritis: Delayed onset of optimal efficacy. Cyclosporine in RA 1964, 71-88.
41. Paero, G., Priolo, F., Marubini, E. et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996, 39: 1006-15.
42. Drosos, A.A., Voulgari, P.V., Georgiou, P.E., Zikou, A.K. Retardation of radiologic progression in early rheumatoid arthritis patients treated with cyclosporine A: A 36-month prospective study. Arthritis Rheum 1997, 40 (Suppl.): S54.
43. Panayi, G.S. The immunopathogenesis of rheumatoid arthritis. Br J Rheum 1993, 32 (Suppl. 1): 4-14.
44. Kurosaka, M., Ziff, M. Immunoelectron microscopic study of distribution of T-cell subsets and HLA-DR expressing cells in rheumatoid synovium. Arthritis Rheum 1983, 26: S53.
45. Haraoui, B., Wilder, R.L., Malone, D.G., Allen, J.B., Katona, I.M., Wahl, S.M. Immune function in severe, active rheumatoid arthritis: A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and mononuclear cell subset profiles. J Immunol 1984, 133: 697-701.
46. Malone, D.G., Wahl, S.M., Tsokos, M., Cattel, H., Decker, J.L., Wilder, R.L. Immune function in severe, active rheumatoid arthritis: A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characteristics. J Clin Invest 1984, 74: 1173-85.
47. Csuka, M., Carreara, G.F., McCarty, D.J. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine and hydroxychloroquine: A follow-up study. JAMA 1986, 255: 2315-19.
48. Amor, B., Herson, D., Cherot, A. et al. Follow-up study of patients with rheumatoid arthritis over a period of more than 10 years (1966-1978): Analysis of disease progression and treatment in 100 cases. Ann Med Intern 1981, 132: 168-73.
49. Segal, R., Mozes, E., Yaron, M., et al. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989, 32: 370-7.
50. Brahn, E., Peacock, D.J., Banquerigo, M.L. Suppression of collagen-induced arthritis by combination cyclosporin A and methotrexate therapy. Arthritis Rheum 1991, 34: 1282-8.
51. Tugwell, P., Pincus, T., Yocum, D., et al. A multi-centre, double-blind, randomized trial of low-dose cyclosporin and placebo therapy in combination with methotrexate in patients with severe rheumatoid arthritis. New Engl J Med 1995, 333: 137-41.
52. Stein, C.M., Pincus, T., Brooks, R.H. et al. Combination therapy with cyclosporine and methotrexate: Results of a 24-week extension study subsequent to a 24-week double-blind study. Arthritis Rheum 1994, 37: S252.
53. Ferraccioli, G.F., Di Poi, E., Damato, R., Casatta, L., De Vita, S., Bartoli, E. Analysis of remission and full responses in rheumatoid arthritis patients treated with combination therapy for three years. Arthritis Rheum 1997, 40 (Suppl.): S219.
54. Landewé, R.B.M., Miltenburg, A.M.M., Breedveld, F.C., Daha, M.R., Dijkmans, B.A.C. Cyclosporine and chloroquine synergistically inhibit the Interferon-γ production by CD4-positive and CDS-positive synovial T-cell clones derived from a patient with rheumatoid arthritis. Cyclosporine in RA 1964, 111-23.
55. Landewé, R.B.M., Miltenburg, A.M.M., Verdonk, M.J.A., et al. Cyclosporine and chloroquine synergistically inhibit T-cell proliferation by interference with IL-2 production and IL-2 responsiveness. Cyclosporine in RA 1964, 125-46.
56. Dijkmans, B.A.C. et al. Chloroquine combined with cyclosporine in rheumatoid arthritis: more than addition of 2 drugs alone. J Rheumatol 1996, 23: 61-4.
57. Salaffi, F., Carotti, M. Cervini, C. Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis. Scand J Rheumatol 1996, 25: 16-23.
58. Bensen, W., Tugwell, P., Roberts, R. et al. Combination therapy of cyclosporin with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheum 1994, 21: 2034-8.
59. Yocum, D. Immunological actions of cyclosporin A in rheumatoid arthritis. Br J Rheum 1993, 32 (Suppl. 1): 38-41.
60. Yocum, D.E., Wilder, R.L., Dougherty, S. et al. Immunological parameters of response in patients with rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1990, 33: 1310-16.
61. Walsh, B.T., Seaver, N., Bennett, R. et al. Immunologic profile of rheumatoid arthritis patients treated with cyclosporin A and methotrexate: Results from a double-blind placebo-controlled trial. Arthritis Rheum 1992, 35: S216.
62. Yocum, D.E., Cornett, M., Olson, S., Nordensson, K. Effects of methotrexate and methotrexate plus cyclosporine on mononuclear cell proliferation and lymphocyte surface markers in rheumatoid arthritis patients: Results of a double-blind trial. Arthritis Rheum 1994, 37: S52.
63. Starzl, T.E., Fung, J., Jordan, M., et al. Kidney transplantation under FK 506. JAMA 1990, 264: 63-7.
64. Miyahara, H., Hotokebachi, T., Arita, C. et al. Comparative studies of the effects of FK 506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. Clin Immunol Immunopathol 1991, 60: 278-88.
65. Arita, C., Hotokebuchi, T., Miyahara, H. et al. Inhibition by FK-506 of established lesions of collagen-induced arthritis in rats. Clin Exp Immunol 1990, 82: 456-61.
66. Seterah, M., Yocum, D.E., Parsons, J. Inhibition of streptococcal cell wall-induced arthritis by rapamycin. Personal communication.
67. Euqui, E.M., Almquist, S.J., Muller, C.D., Allison, A.C. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991, 33: 1616-173.
68. Platz, K.P., Sollinger, H.W., Hulleh, D.A. et al. Rs-61443 - A new, potent immunosuppressive agent. Transplantation 1991, 51: 27-31.
69. Schiff, M.H., Goldblum, R., Rees, M.M.C. New DMARD, mycophenolate mofetil, effectively treats refractory rheumatoid arthritis patients for one year. Arthritis Rheum 1991, 34(Suppl.): S89.
70. Goldblum, R., Rees, M.M.C., Eaqui, E., Schiff, M.H. Immunologic changes in patients with rheumatoid arthritis treated for one year with a new DMARD, mycophenolate mofetil. Arthritis Rheum 1991, 34 (Suppl.): S157.
71. Schiff, M., Stein, G., Leishman, B. Cellcept® (mycophenolate mofetil-MMF), a new treatment for RA: A 9-month, randomized, double-blind trial comparing 1g bid and 2g bid. Arthritis Rheum 1997, 40 (Suppl.): S194.
72. Strand, V., Lipsky, P., Cannon, G. et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: Results of two phase II studies. Arthritis Rheum 1993, 36: 620-30.
73. Wendung, D., Racadot, E., Morel-Fourrier, B., Wijdenes, J. Treatment of rheumatoid arthritis with anti-CD4 monoclonal antibody: Open study of 25 patients with the B-F5 clone. Clin Rheumatol 1992, 11: 542-7.
74. Horneff, G., Burmeister, G.R., Emmrich, F., Kalden, J.R. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991, 34: 129-40.
75. Moreland, L.W., Bucy, R.P., Tilden, A. et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993, 36: 307-18.
76. Choy, E.H.S., Chikanza, I.C., Kingsley, G.H., Corrigal, V., Panayi, G. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimeric anti-CD4 monoclonal antibody. Scand J Immunol 1992, 36: 291-8.
77. + T-cells. Arthritis Rheum 1994, 37: 834-8.
78. Isaacs, J.D., Watts, R.A., Hazleman, B.L. et al. Humanized monoclonal therapy for rheumatoid arthritis. Lancet 1992, 340: 748-52.
79. Matteson, E.L., Yocum, D.E., St. Clair, E.W. et al. Treatment of refractory rheumatoid arthritis with humanized monoclonal antibody Campath 1H administered by daily subcutaneous injection. Arthritis Rheum 1995, 38: 1187-93.
80. Newman, R., Alberts, J., Anderson, D. et al. "Primatization" of recombinant antibodies for immunotherapy of human diseases: A macaque/human chimeric antibody against human CD4. Biotechnology 1992, 10: 1455-60.
81. Yocum, D.E., Solinger, A.M., Lipani, J., Tesser, J., Gluck, O., Cornett, M. Clinical and immunopharmacologic effects of primatized IDEC-CE9.1, a monoclonal anti-CD4 antibody in a phase I trial in active rheumatoid arthritis. Clin Res 1995, 43: 363A.
82. Kaine, J., Solinger, A., Yocum, D. et al. Results of a multi-dose protocol 7002 using an immunomodulating non-depleting primatized anti-CD4 monoclonal antibody: Results of a multidose study. Arthritis Rheum 1995, 38: S280.
83. Levy, R., Weismann, M., Wiesenhutter, C. et al. Results of a placebo-controlled, multi-center trial using a primatized non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis. Arthritis Rheum 1996, 39: S122.
84. Panayi, G.S., Choy, E.H.S., Connolly, D.J.A. et al. T-cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monoclonal antibody (mAb) treatment I: Suppression of disease activity and acute phase response. Arthritis Rheum 1996, 39: S244.
85. Weinblatt, M.E., Maddison, P.J., Bulpitt, K.S. et al. Campath-1H humanized monoclonal antibody in refractory rheumatoid arthritis: An intravenous dose-escalation study. Arthritis Rheum 1995, 38: 1589-94.
86. Ruderman, E.M., Weinblatt, M.E., Thurmond, L.M., Pinkus, G.S., Gravallese E.M. Synovial tissue response to treatment with Campath-1H. Arthritis Rheum 1995, 38: 254-8.
87. Cooper, S.M., Dier, D.L., Roessner, K.D. et al. Diversity of rheumatoid synovial tissue T-cells by T-cell receptor analysis: Oligoclonal expansion in interleukin-2 responsive cells. Arthritis Rheum 1991, 34: 537.
88. Chatila, M.K., Pandolfi, F., Stamenkovich, I. et al. Clonal dominance among synovial tissue-infiltrating lymphocytes in arthritis. Hum Immunol 1990, 28: 252.
89. Duby, A.D., Sinclair, A.K., Osborne-Lawrence, S.L. et al. Clonal heterogeneity of synovial fluid T-lymphocytes from patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1989, 86: 6206.
90. Moreland, L.M., Heck, L.W. Jr., Koopman, W.J. et al. Vβ T-cell receptor peptide vaccination in rheumatoid arthritis: Results of a phase I dose escalation study. J Rheumatol 1996, 23: 1353-62.
91. Sany, J. Treatment of rheumatoid arthritis by antibodies directed against class II MHC antigens. Scand J Rheumatol 1988, 76 (Suppl.): 289.
92. St. Clair, E.W., Cohen, S.B., Fleischman, R.M. et al. Vaccination of rheumatoid arthritis (RA) patients with DR4/1-peptide. Arthritis Rheum 1997, 40: S96.